MRFR Year End Sale
Schizophrenia Market Research Report - Forecast till 2030

Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/1094-HCR | December 2022 | Region: Global | 90 Pages         

Schizophrenia Market

Schizophrenia Market to register a CAGR of 4.90% and reach a value of USD 7,180 Million by 2030.

Segmentation

by Type Paranoid Schizophrenia Hebephrenic Schizophrenia Catatonic Schizophrenia and Undifferentiated Schizophrenia
By Treatment second-generation antipsychotics third-generation antipsychotics
By Route Of Administration oral Injectables

Key Players

  • Johnson & Johnson (US)
  • Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals (US)
  • AstraZeneca (UK)
  • Eli Lilly (US)
  • Alkermes (Ireland)
  • Sumitomo Dainippon Pharma (Japan)
  • Pfizer (US)
  • Vanda Pharmaceuticals (US)
  • Allergan/Geodon Ritcher (Ireland)

Drivers

  • increased investment and expenditure
Speak to Analyst Request a Free Sample

Schizophrenia Market Overview


The Schizophrenia Market is expected to reach USD 7,180 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030. Schizophrenia is a mental illness that includes delusions, hallucinations, and other cognitive difficulties. It is a long-term struggle that can remain till the end. It is a severe mental disorder that affects people's thoughts, feelings, and behavior. The growth of mental disorder conditions due to the factors like stress, depression, anxiety and genetic disorder has increased the demand of the Market.


The concern among the public across the world for understanding mental health conditions and disorders has led to the increase in Schizophrenia Market Trends. The governments of different countries collaborate with hospitals to protect people from schizophrenia.


The primary growth factors accelerating the Schizophrenia Market Growth include the rise in cases of schizophrenia, growth of senior individuals, and increase in research and development activities for schizophrenia treatment. Schizophrenia has become the leading cause of disability worldwide. This has raised the concern of government and other health care organizations, which shows a positive impact on the market. 


The rising incidences of schizophrenia in developed countries, awareness among individuals for treating schizophrenia, and increase in popularity for long-acting injectable (LAI) antipsychotics are major factors driving the Schizophrenia Market Size. 


Other regions, such as the higher number of pipeline drugs and the availability of cost-effective schizophrenia drugs, will boost up the Market over the forecast period.


COVID-19 Analysis


During the pandemic period, various markets faced a downfall in growth. Some of them noticed a good growth rate, especially the market related to the health sector showed an increase in the market value. At the initial stage, the Market faced challenges due to the lockdown, which affected the manufacturing units and halted the export of medications. But in the further days of the pandemic, the concern for mental health increased. The risk of getting infected by COVID-19 with a mental condition like schizophrenia has increased the demand of the Schizophrenia Market across the globe. The health conditions with schizophrenia can contribute to serious COVID-19 symptoms, which raised the market value. The awareness provided to mental health patients during the pandemic has helped the market to stimulate its growth. Even in the post-pandemic period, the Market is estimated to maintain its demand.


Chief Factors Existing In The Market



  • Key Market Drivers


The presence of growth drivers of the Schizophrenia Market is responsibly driving it at the global level. The growth factors are the increased investment and expenditure in mental health illness is acting as the major driving factor. The surge in chronic ailments illness and the growing number of incidences in developed countries is another market driver. As the schizophrenia disease population is growing, the demand for special and effective medications is chiefly driving the market. 



  • Market Challenges


The Schizophrenia Market is facing challenges affecting the market during its growth period. The lack of effective awareness in underdeveloped countries related to the risk of mental health problems is challenging the market. Lack of proper sources to reach people suffering from mental health and making them aware of effective medications are challenging market factors.



  • Market Opportunities


The Schizophrenia Market is receiving good growth opportunities for various reasons, such as the rise in concern for mental health conditions. The rise in the number of patients and the growing demand for improved healthcare infrastructure set huge opportunities for the market. 



  • Market Restraints


There is growth limiting factors that are hampering the Schizophrenia Market Growth. The higher cost for the treatment and medications are acting as market restraints. The side effects of the drugs developed for the treatment of schizophrenia affect the market's growth rate. Another major constraint is the lack of proper knowledge in healthcare, especially in the underdeveloped regions are showing a bad impact on the market. The stringent regulations for new product approvals and launches also affect the global market.


Cumulative Evaluation Of The Market


The evaluation of the Schizophrenia Market Analysis shows the presence of market dynamics and their effects on the market. Due to the growth drivers and opportunities, the market is propelling at a higher pace. The negative impact of the challenging and restraining factors are hampering the market's growth. The pandemic has shown a good impact on the market as the concern for mental health conditions reached during the period. The market overview stated the growth since the past years and its further estimated growth value. The Market is estimated to reach a strong CAGR during the forecasted period.


Market Segmentation


The Schizophrenia Market is segregated into type, treatment, and route of administration. These major segments are further classified into various sub-segments.



  • By Type


The type segment of the Schizophrenia Market is classified into paranoid schizophrenia, catatonic schizophrenia, hebephrenic schizophrenia, and undifferentiated schizophrenia.



  • By Treatment


The treatment is classified into second-generation antipsychotics and third-generation antipsychotics. The second-generation antipsychotics segment is further divided into Zyprexa (Olanzapine), Geodon (Ziprasidone), Risperdal (Risperidone), Invega (Paliperidone), Seroquel (Quetiapine), Latuda (Lurasidone), and others.



  • By Route Of Administration


The route of the administration segment is bifurcated into oral and injectables.


Regional Analysis


According to the geographical analysis, the Schizophrenia Market shows its major growth in regions such as the Americas, Europe, Asia-Pacific, the Middle East and Africa.


It has been noticed that America is the dominating region of the market due to the increasing cases of schizophrenia, an increased growth rate of the geriatric population, and the rising demand for schizophrenia treatment driving the region's regional market. Other factors are driving the region, such as the conduct of awareness programs, which are accelerating the regional market. 


The European market is considered as the second-largest region, followed by America as it holds the Schizophrenia Market Share due to the increase in health problems and rises in the senior population. The higher expenditure in the healthcare sector due to the rise in concern for mental health is boosting the European market. 


The Asia-Pacific region is observed as the rapidly growing region of the market due to the huge population and rise in demand for technologically advanced and improved treatments. The occurrence of mental illness has been noticed higher in developing countries like Japan, Hong Kong, and Singapore, which is contributing to the APAC market's growth.


The Middle East and African region are occupying the least share value of the Schizophrenia Market due to the presence of lesser healthcare facilities and lower per capita income. People of underdeveloped countries of this region are not aware of the treatment methods related to the disease. Bu the market is estimated to witness growth due to the development of hospitals, and growing demand for schizophrenia treatment products in the Middle East region will fuel up its regional growth.


Competitive Intensity Within The Industry 


The industrial players of the Market are accelerating the growth at the global level with their developments. The recent and future developments that include approvals, drug launches and other improvements are helping the market to merge in various regions. The collaborations of the players with the health care providers and the governments are providing them huge opportunities to compete at the top level. Below mentioned are the top industrial players of the Schizophrenia Market Outlook.



  • Johnson & Johnson (US)

  • Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals (US)

  • AstraZeneca (UK)

  • Eli Lilly (US)

  • Alkermes (Ireland)

  • Sumitomo Dainippon Pharma (Japan)

  • Pfizer (US), Vanda Pharmaceuticals (US)

  • Allergan/Geodon Ritcher (Ireland)


Recent Market Developments



  • In June 2020, Karuna Therapeutics declared the Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT. The product candidate KarXT is evaluated for the Treatment of Acute Psychosis in Patients suffering from Schizophrenia.

  • Alkermes won Lybalvi's FDA approval last June for treating schizophrenia and bipolar disorder. It engineered a soft launch four months later in October. The drug brought was $8.2 million in the fourth quarter, but Alkermes predicts net sales of $55 million to $75 million in this year.


Report Overview


The report of the Schizophrenia Market study shows the growth factors which are boosting up its growth. The effect of market dynamics is also mentioned as well as the positive impact of the pandemic is also discussed in detail. The segmentation report stated the crucial market segments, and the regional distribution has shown the regions covered by the market. The role of key players along with their developments was stated. Further, the Market is estimated to reach a significant value in the review period.


Key Industrial Segments


By Type



  • Paranoid Schizophrenia

  • Hebephrenic Schizophrenia

  • Catatonic Schizophrenia 

  • Undifferentiated Schizophrenia


By Treatment 



  • Second-Generation Antipsychotics 

  • Risperdal (Risperidone)

  • Invega (Paliperidone)

  • Zyprexa (Olanzapine)

  • Geodon (Ziprasidone)

  • Seroquel (Quetiapine)

  • Latuda (Lurasidone)

  • Third-Generation Antipsychotics and others


By Route of Administration 



  • Oral 

  • Injectables



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 7,180 Million
  CAGR   4.90%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and Route of Administration
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Johnson & Johnson (US), Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals (US), AstraZeneca (UK), Eli Lilly (US), Alkermes (Ireland), Sumitomo Dainippon Pharma (Japan), Pfizer (US), Vanda Pharmaceuticals (US), and Allergan/Geodon Ritcher (Ireland)
  Key Market Opportunities   stringent regulations around new product approvals and rising generic launches
  Key Market Drivers

  • rising cases of schizophrenia
  • growing number of geriatric individuals
  • increasing research and development in schizophrenia treatment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Schizophrenia Market can expand at 4.90% CAGR from 2022 to 2030.

    The Global Schizophrenia Market stood at USD 7,180 Million in 2030.

    Developments in schizophrenia treatment, rising cases of the disorder, and the growing numbers of the geriatric populace are major drivers of the Global Schizophrenia Market.

    The Global Schizophrenia Market growth can be hampered by generic launches and approvals of new products.

    Alkermes, Allergan/Geodon Ritcher, Johnson & Johnson, AstraZeneca, Eli Lilly, Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals, Pfizer, Sumitomo Dainippon Pharma, and Vanda Pharmaceuticals are prominent players of the Global Schizophrenia Market.